Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Devonian Health Group Inc V.GSD

Alternate Symbol(s):  DVHGF

Healthcare Biotechnology
Devonian Health Group Inc. is a clinical-stage pharmaceutical company. It specializes in the development of drugs for various autoimmune inflammatory conditions with novel therapeutic approaches to targeting unmet medical needs. It is developing prescription drugs for the treatment of inflammatory autoimmune diseases, including but not limited to, ulcerative colitis and atopic dermatitis. It is also involved in the development of cosmeceutical products, leveraging the same proprietary approach employed with their pharmaceutical offerings. Its flagship product, Thykamine, is a pharmaceutical product issued from its SUPREX platform, for the prevention and treatment of health problems related to inflammation and oxidative stress, including ulcerative colitis, atopic dermatitis, psoriasis, rheumatoid arthritis, and other autoimmune diseases. Its cosmeceutical products include R-Spinasome and Purgenesis. Its subsidiary, Altius Healthcare Inc., sells prescription pharmaceutical products.


TSXV:GSD - Post by User

Devonian Health Group Inc
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(1470)
•••
  • lscfaX
Post by lscfaon Feb 07, 2025 11:36pm
75 Views
Post# 36443968

Bad news

Bad news
Devonian Reports Distribution Agreement Termination
 
QUEBEC CITY--(BUSINESS WIRE)--February 7, 2025--Devonian Health Group Inc. (“Devonian” or the
“Corporation”) (TSXV: GSD; OTCQB: DVHGF), a clinical stage corporation focused on developing unique
solutions to inflammatory diseases, today announced that its pharmaceutical distribution division, Altius
Healthcare Group L.P. ("Altius"), has been informed that one of its licensor does not intend to exercise its
contractual license renewal option for the distribution of Dexlansoprazole for an additional term. Revenue for
Dexlansoprazole represented 86% and 92% of Devonian’s total reported revenues for the fiscal year ended July
31, 2024, and the quarter ended October 31,2024, respectively. The Corporation will continue selling
Dexlansoprazole until April 17, 2025, when the licence agreement will terminate, and will continue to sell
Pantoprazole Magnesium and Cleo-35® thereafter.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities